Protein-Small Molecule Docking Service for Hit Identification & Lead Optimization

Case 1

Rational design and optimization of IRAK4 inhibitors

Research summary: This study demonstrates how molecular docking is integrated into a rational drug design pipeline targeting Interleukin-1 Receptor-Associated Kinase 4 (IRAK4), a critical target for cancer and autoimmune diseases. The researchers initially utilized molecular docking and molecular dynamics (MD) simulations to analyze the binding modes of known active compounds within the IRAK4 binding pocket. By employing MM-PBSA calculations, they identified key residues essential for stable binding, providing a structural foundation for subsequent optimization.

Based on these structural insights, a 3D-QSAR model was developed to correlate molecular features with biological activity. This model served as a predictive guide for designing novel IRAK4 inhibitors with enhanced theoretical potency. This case exemplifies the "analysis-modeling-design" closed-loop approach, where docking serves as a core tool to drive the discovery of small-molecule inhibitors through rigorous computational validation.

Figure 1. Alignment of the dataset compounds inside the active site of IRAK4.^1,3

Bhujbal S P, He W, Hah J M. Molecules, 2022, 27(19): 6307. 10.3390/molecules27196307

Case 2

Repurposing nanomaterials as viral protease inhibitors

Research summary: This research expands the application of protein-ligand docking into the field of nanomaterials by exploring fullerenes as potential inhibitors of the SARS-CoV-2 Main Protease (Mpro). Through molecular docking, the authors predicted that C60 and C70 fullerenes could fit precisely into the active site of the protease. These findings were further validated using molecular dynamics simulations and MM-GBSA binding free energy calculations to ensure the stability of the carbon-based structures within the protein environment.

The computational results revealed that these carbon nanomaterials bind to Mpro through exceptional shape complementarity and strong Van der Waals interactions. Remarkably, their binding affinity outperformed Masitinib, a known small-molecule inhibitor, and remained stable regardless of the protonation states of catalytic residues. This work provides an innovative computational pathway for exploring non-traditional molecules, such as nanomaterials, as potent antiviral agents.

Figure 2. (A) C70@Mpro interactions. ΔGbinding decomposed per residue. (B) Interaction between His41, Cys44, Met49, Cys145, Met165, and Gln189 and C70.^2,3

Marforio T D, Mattioli E J, Zerbetto F, et al. Molecules, 2022, 27(6): 1916. 10.3390/molecules27061916

References:

1. Bhujbal S P, He W, Hah J M. Design of novel IRAK4 inhibitors using molecular docking, dynamics simulation and 3D-QSAR studies. Molecules, 2022, 27(19): 6307. 10.3390/molecules27196307
2. Marforio T D, Mattioli E J, Zerbetto F, et al. Fullerenes against COVID-19: Repurposing C60 and C70 to clog the active site of SARS-CoV-2 protease. Molecules, 2022, 27(6): 1916. 10.3390/molecules27061916
3. Distributed under Open Access license CC BY 4.0, without modification.

* For Research Use Only.